NZ592507A - Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers - Google Patents
Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockersInfo
- Publication number
- NZ592507A NZ592507A NZ592507A NZ59250709A NZ592507A NZ 592507 A NZ592507 A NZ 592507A NZ 592507 A NZ592507 A NZ 592507A NZ 59250709 A NZ59250709 A NZ 59250709A NZ 592507 A NZ592507 A NZ 592507A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pyrrol
- octahydrocyclopenta
- calcium channel
- compounds
- octahydrocyclopnta
- Prior art date
Links
- WAUGGYPDCQZJKK-UHFFFAOYSA-N 1h-pyrrol-3-amine Chemical class NC=1C=CNC=1 WAUGGYPDCQZJKK-UHFFFAOYSA-N 0.000 title 1
- 229940127291 Calcium channel antagonist Drugs 0.000 title 1
- 239000000480 calcium channel blocker Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- PJQNPTHRIJPDSO-AITUJVMLSA-N (2s)-n-[(3as,4r,6ar)-2-[(4-fluorophenyl)methyl]-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1C[C@H]2[C@H](NC(=O)[C@H]3NCCCC3)CC[C@H]2C1 PJQNPTHRIJPDSO-AITUJVMLSA-N 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11799508P | 2008-11-26 | 2008-11-26 | |
| PCT/US2009/065847 WO2010062927A2 (en) | 2008-11-26 | 2009-11-25 | Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592507A true NZ592507A (en) | 2013-08-30 |
Family
ID=42124348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592507A NZ592507A (en) | 2008-11-26 | 2009-11-25 | Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8129417B2 (OSRAM) |
| EP (1) | EP2367790A2 (OSRAM) |
| JP (1) | JP2012509940A (OSRAM) |
| KR (1) | KR20110091784A (OSRAM) |
| CN (1) | CN102292319A (OSRAM) |
| AR (1) | AR074226A1 (OSRAM) |
| AU (1) | AU2009319796A1 (OSRAM) |
| BR (1) | BRPI0921184A2 (OSRAM) |
| CA (1) | CA2742350A1 (OSRAM) |
| CL (1) | CL2011001176A1 (OSRAM) |
| CO (1) | CO6382118A2 (OSRAM) |
| CR (1) | CR20110304A (OSRAM) |
| EC (1) | ECSP11011160A (OSRAM) |
| IL (1) | IL212484A0 (OSRAM) |
| MX (1) | MX2011005537A (OSRAM) |
| NZ (1) | NZ592507A (OSRAM) |
| PA (1) | PA8850301A1 (OSRAM) |
| PE (1) | PE20110833A1 (OSRAM) |
| RU (1) | RU2011126215A (OSRAM) |
| TW (1) | TW201028378A (OSRAM) |
| UY (1) | UY32261A (OSRAM) |
| WO (1) | WO2010062927A2 (OSRAM) |
| ZA (1) | ZA201103538B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074226A1 (es) | 2008-11-26 | 2010-12-29 | Abbott Lab | Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor. |
| US8211933B2 (en) * | 2008-12-12 | 2012-07-03 | Vanderbilt University | 3.3.0 bicyclic GlyT1 inhibitors and methods of making and using same |
| WO2011115813A1 (en) * | 2010-03-18 | 2011-09-22 | Abbott Laboratories | Lactam acetamides as calcium channel blockers |
| WO2011149995A1 (en) * | 2010-05-25 | 2011-12-01 | Abbott Laboratories | Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers |
| US8796470B2 (en) | 2010-05-25 | 2014-08-05 | Abbvie Inc. | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators |
| FR2976285B1 (fr) * | 2011-06-08 | 2013-05-24 | Servier Lab | Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent |
| WO2013049164A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| WO2013049174A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| KR20150093237A (ko) | 2012-12-12 | 2015-08-17 | 애브비 인코포레이티드 | 통증 치료시 칼슘 채널 차단제로서 유용한 디아제핀 유도체 |
| WO2017063563A1 (zh) * | 2015-10-13 | 2017-04-20 | 四川海思科制药有限公司 | 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途 |
| CN118684652A (zh) * | 2017-09-11 | 2024-09-24 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
| US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
| AU2020480829A1 (en) | 2020-12-07 | 2023-07-20 | Kimberly-Clark Worldwide, Inc. | Methods and consumer products for detecting a metabolite |
| WO2022211060A1 (ja) | 2021-04-01 | 2022-10-06 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニスト |
| KR20240046089A (ko) | 2022-09-30 | 2024-04-08 | 오노 야꾸힝 고교 가부시키가이샤 | Abhd6 길항제를 함유하는 약학 조성물 |
| JP7852604B2 (ja) * | 2022-09-30 | 2026-04-28 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニストを含有する医薬組成物 |
| TW202421635A (zh) | 2022-09-30 | 2024-06-01 | 日商小野藥品工業股份有限公司 | Abhd6拮抗劑 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0278659A (ja) | 1988-09-12 | 1990-03-19 | Shionogi & Co Ltd | アザビシクロアルカン類化合物 |
| DE60011755T2 (de) * | 1999-04-07 | 2005-06-30 | The University Of Virginia Patent Foundation | Calciumkanalblocker als antikrebsmittel |
| US8163769B2 (en) * | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| US7223754B2 (en) * | 2003-03-10 | 2007-05-29 | Dynogen Pharmaceuticals, Inc. | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders |
| WO2004083207A1 (en) * | 2003-03-12 | 2004-09-30 | Abbott Laboratories | Naphthyridine derivatives as antibacterial agents |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7230022B2 (en) * | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| JP2008507543A (ja) * | 2004-07-22 | 2008-03-13 | グラクソ グループ リミテッド | 抗細菌剤 |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2006113471A2 (en) | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| CN102239146A (zh) * | 2008-10-02 | 2011-11-09 | 雅培制药有限公司 | 作为钙通道阻断剂的新化合物 |
| AR074226A1 (es) | 2008-11-26 | 2010-12-29 | Abbott Lab | Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor. |
| US8211933B2 (en) * | 2008-12-12 | 2012-07-03 | Vanderbilt University | 3.3.0 bicyclic GlyT1 inhibitors and methods of making and using same |
-
2009
- 2009-11-25 AR ARP090104557A patent/AR074226A1/es not_active Application Discontinuation
- 2009-11-25 RU RU2011126215/04A patent/RU2011126215A/ru not_active Application Discontinuation
- 2009-11-25 CA CA2742350A patent/CA2742350A1/en not_active Abandoned
- 2009-11-25 EP EP09764953A patent/EP2367790A2/en not_active Withdrawn
- 2009-11-25 PA PA20098850301A patent/PA8850301A1/es unknown
- 2009-11-25 BR BRPI0921184A patent/BRPI0921184A2/pt not_active IP Right Cessation
- 2009-11-25 MX MX2011005537A patent/MX2011005537A/es unknown
- 2009-11-25 WO PCT/US2009/065847 patent/WO2010062927A2/en not_active Ceased
- 2009-11-25 NZ NZ592507A patent/NZ592507A/xx not_active IP Right Cessation
- 2009-11-25 TW TW098140141A patent/TW201028378A/zh unknown
- 2009-11-25 AU AU2009319796A patent/AU2009319796A1/en not_active Abandoned
- 2009-11-25 KR KR1020117014731A patent/KR20110091784A/ko not_active Withdrawn
- 2009-11-25 UY UY0001032261A patent/UY32261A/es not_active Application Discontinuation
- 2009-11-25 JP JP2011538682A patent/JP2012509940A/ja active Pending
- 2009-11-25 US US12/625,754 patent/US8129417B2/en not_active Expired - Fee Related
- 2009-11-25 CN CN2009801553748A patent/CN102292319A/zh active Pending
- 2009-11-25 PE PE2011001093A patent/PE20110833A1/es not_active Application Discontinuation
-
2011
- 2011-04-26 IL IL212484A patent/IL212484A0/en unknown
- 2011-05-13 ZA ZA2011/03538A patent/ZA201103538B/en unknown
- 2011-05-19 CL CL2011001176A patent/CL2011001176A1/es unknown
- 2011-05-27 CO CO11065858A patent/CO6382118A2/es not_active Application Discontinuation
- 2011-06-06 CR CR20110304A patent/CR20110304A/es not_active Application Discontinuation
- 2011-06-24 EC EC2011011160A patent/ECSP11011160A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010062927A2 (en) | 2010-06-03 |
| CR20110304A (es) | 2011-10-27 |
| IL212484A0 (en) | 2011-06-30 |
| PE20110833A1 (es) | 2011-12-21 |
| US20100130558A1 (en) | 2010-05-27 |
| CL2011001176A1 (es) | 2011-11-11 |
| TW201028378A (en) | 2010-08-01 |
| KR20110091784A (ko) | 2011-08-12 |
| BRPI0921184A2 (pt) | 2018-03-13 |
| WO2010062927A3 (en) | 2010-07-22 |
| CN102292319A (zh) | 2011-12-21 |
| JP2012509940A (ja) | 2012-04-26 |
| RU2011126215A (ru) | 2013-01-10 |
| ECSP11011160A (es) | 2011-07-29 |
| AU2009319796A8 (en) | 2011-06-30 |
| MX2011005537A (es) | 2011-06-21 |
| CA2742350A1 (en) | 2010-06-03 |
| US8129417B2 (en) | 2012-03-06 |
| AU2009319796A1 (en) | 2010-06-03 |
| PA8850301A1 (es) | 2010-07-27 |
| ZA201103538B (en) | 2012-11-28 |
| EP2367790A2 (en) | 2011-09-28 |
| CO6382118A2 (es) | 2012-02-15 |
| UY32261A (es) | 2010-06-30 |
| AR074226A1 (es) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
| NO20076447L (no) | Bicykliske derivater som modulatorer av ionekanaler | |
| NZ596579A (en) | Bace inhibitors | |
| IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
| MY146972A (en) | Novel compounds as opioid receptor modulators. | |
| NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
| WO2010002956A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
| MY146494A (en) | Indole sulfonamide modulators of progesterone receptors | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| NZ599343A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
| MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
| MX2010003866A (es) | Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| TW200613272A (en) | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | |
| EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
| MX2007007103A (es) | Derivados espiro como inhibidores de lipoxigenasa. | |
| ATE520690T1 (de) | Piperidinderivate als renin-inhibitoren | |
| ATE540036T1 (de) | Heterocyclische derivate als ionenkanalmodulatoren | |
| MX2009002842A (es) | Inhibidores heterociclicos de c-met y usos de los mismos. | |
| WO2011149993A3 (en) | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| MX2022015022A (es) | Composiciones farmaceuticas de pralsetinib. | |
| SG158925A1 (en) | Modulators of chemokine receptor activity, crystalline forms and process | |
| PE20060477A1 (es) | Compuestos piperazinodionas como antagonistas del receptor de oxitocina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ABBVIE INC., US Effective date: 20130801 |
|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |